SCHEMBL9010495

SCHEMBL9010495

CCOC(=O)C(=CNN)C(=O)OCC

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.60
ALDH1A1 P00352 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
NPSR1 Q6W5P4 3/20 0.52
GLO1 Q04760 1/20 0.52
DHODH Q02127 3/20 0.51
GAA P10253 4/20 0.49
MAPT P10636 4/20 0.49
TDP1 Q9NUW8 1/20 0.49
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
CYP3A4 P08684 2/20 0.46
CYP1A2 P05177 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C19 P33261 1/20 0.44
EGLN1 Q9GZT9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26012486 0.80 CYP2D6 (0.62) CYP2D6ALDH1A1SMN1; SMN2NPSR1GLO1
SCHEMBL26084789 0.79 CYP2D6 (0.56) CYP2D6ALDH1A1SMN1; SMN2NPSR1GLO1
SCHEMBL10314666 0.78 CYP2D6 (0.71) CYP2D6ALDH1A1SMN1; SMN2NPSR1GLO1
SCHEMBL11517764 0.77 CYP2D6 (0.58) CYP2D6ALDH1A1SMN1; SMN2NPSR1GLO1
SCHEMBL9326451 0.77 CYP2D6 (0.58) CYP2D6ALDH1A1SMN1; SMN2NPSR1GLO1
SCHEMBL26608078 0.75 CYP2D6 (0.56) CYP2D6ALDH1A1SMN1; SMN2NPSR1GLO1
SCHEMBL27790849 0.75 CYP2D6 (1.00) CYP2D6ALDH1A1SMN1; SMN2NPSR1GLO1
SCHEMBL1543791 0.75 NPSR1 (0.58) CYP2D6ALDH1A1SMN1; SMN2NPSR1GLO1
SCHEMBL1942274 0.74 NPSR1 (0.62) CYP2D6ALDH1A1SMN1; SMN2NPSR1GLO1
SCHEMBL15273109 0.74 GLO1 (0.77) CYP2D6ALDH1A1SMN1; SMN2NPSR1GLO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0741320-A1 Photothermographic Photosensitive Recording Material with Hugh Gradient DU PONT DE NEMOURS (DEUTSCHLAND) GMBH (DE) 1996-11-06 EP claimed
EP-2687515-A1 METHOD FOR PRODUCING PYRAZOLECARBOXYLIC ACID DERIVATIVE Shionogi & Co., Ltd. (JP) 2014-01-22 EP disclosed
US-20140012013-A1 METHOD FOR PRODUCING PYRAZOLE CARBOXYLIC ACID DERIVATIVE SHIONOGI & CO., LTD. (JP) 2014-01-09 US disclosed
EP-0741320-A1 Photothermographic Photosensitive Recording Material with Hugh Gradient DU PONT DE NEMOURS (DEUTSCHLAND) GMBH (DE) 1996-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140012013-A1 METHOD FOR PRODUCING PYRAZOLE CARBOXYLIC ACID DERIVATIVE HSD11B1, HSD11B2, HSD17B1 CYP2D6 137/4885ALDH1A1 115/4885SMN1; SMN2 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.